Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a mood drug dull the Brain's reaction to light?

NCT ID NCT07750925

Knowledge-focused Sponsor: Northumbria University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial investigates whether taking lithium for a week changes how the eyes and brain respond to light in healthy adults aged 18 to 40. Participants will undergo light exposure sessions with and without lithium, while researchers measure melatonin suppression, alertness, mood, and brain activity. The study aims to uncover how lithium affects light sensitivity at the retina and in central pathways, which could shed light on its role in treating bipolar disorder.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lithium carbonate (Priadel)
What this could lead to
If lithium alters light responses, it could help explain how mood stabilizers work and why light therapy helps some people with bipolar disorder.
What could go wrong
This is a small, early study in healthy volunteers, not patients. Results may not apply to people with bipolar disorder, and lithium can have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 45 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged between 18 and 40 years old * Fluent in English (both spoken and written) * Sleep duration between 6.5 and 9 hours daily * Have a regular normal sleep schedule with bedtime (weekdays) between 21:30 and 01:00. * BMI between 18 and 28kg/m2 * Currently enrolled and registered with a general practitioner * Female participants only: should use effective contraception or refrain from engaging in sexual activity that could result in pregnancy during participation in the study. Exclusion Criteria: * History of psychiatric or neurological disorders * First-degree family history of psychosis or severe mood disorder * Current or past suicidal ideation or self-harm * Current, chronic infections or diseases. * Life-threatening allergies, specifically a nut allergy. * Known visual disorders e.g., colour blindness, glaucoma, cataracts, diabetic retinopathy. * Known medical conditions that could affect the conduct of the study including * sleep disorders * cancer * diabetes * anaemia * epilepsy * psoriasis * thyroid disorders * kidney disease * severe eczema * anemia * migraines * Taking any long-term or regular medications other than oral contraceptives (e.g., antidepressants, diuretics (water-tablets), pain killers or anti-inflammatory drugs (such as ibuprofen) or medications for high blood pressure). * Have donated blood in the past 1 month * Regular or recent recreational drug use * Chronic alcohol addiction/misuse * Known contraindication to magnetic resonance imaging such as pacemaker or metal implants, recent surgery, severe claustrophobia and/or recent head or neck tattoos. * A current smoker (including use of cigarettes, vapes, and/or cigars). * Planning to travel across time zones at any point in time during the conduct of the study or have travelled across time zones within 1 month prior to enrolment. * Currently work night shifts * Been a shift worker in the past 3 months. * Current enrolment in any other interventional studies * Enrolment in any other interventional studies in the 1 month prior to the start of participation in this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bipolar are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bipolar disorder Photophobia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bipolar Healthy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Northumbria University

    Newcastle upon Tyne, Tyne & Wear, NE1 8SG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.